VAL001 – Business Opportunity Summary. A. Mansson, Non-Executive Director, Respiratorius AB. Respiratorius AB develops new and effective candidate drugs for treatment of cancer, COPD and asthma. VAL001 is an orphan drug designated asset that is phase III ready. The indication is Diffuse Large B-Cell Lymphoma (DLBCL).
Respiratorius AB (publ) develops drug candidates with the goal of launching drugs to treat common diseases such as cancer, chronic obstructive pulmonary disease (COPD) and severe asthma. The project portfolio also includes a project for improving the diagnosis of certain cardiovascular diseases using PET imaging.
Scheelevägen 2, 223 81 Lund, Sweden
+46 70 922 41 40